January 31, 2018
Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | ESSA Pharma Inc. |
Registration Statement on FormF-3
FileNo. 333-222654
Ladies and Gentlemen:
ESSA Pharma Inc., a corporation incorporated under the Business Corporations Act (British Columbia), hereby requests, pursuant to Rule 461(a) under the Securities Act of 1933, as amended, that the effective date of the Company’s registration statement (the “Registration Statement”) on FormF-3 (FileNo. 333-222654) be accelerated by the Securities and Exchange Commission (the “Commission”) to 4:00 pm, Eastern Time, on Friday February 2, 2018, or as soon thereafter as practicable.
We request that we be notified of such effectiveness by a telephone call to Colin Brown of Skadden, Arps, Slate, Meagher & Flom LLP, the Company’s counsel, at (416)777-4700 and that such effectiveness also be confirmed in writing.
| Very truly yours, | ||
| ESSA PHARMA INC. | ||
| By: | /s/ David Wood | |
| Name: David Wood | ||
| Title: Chief Financial Officer | ||
